Beijing Xunsheng Biomedical Research Co., Ltd.

Primary objective: To evaluate the safety and efficacy of ReT01 injection in the treatment of advanced cervical cancer. Secondary objective: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of ReT01 ACT injection administered to patients with advanced cervical cancer.

Primary Objectives: 1. To evaluate the safety and tolerability of AVL-101 injection in patients with CIN2/3 caused by untreated human papillomavirus (HPV) 16/18 infection. 2. To determine the recommended dose (RP2D) for the Phase II clinical trial and to preliminarily develop a reasonable dosing regimen. Secondary Objectives: 1. To evaluate whether administration of different dose levels of AVL-101 injection, administered three times at 3-week intervals, can induce anti-HPV16/18 antigen-specific antibodies and cell-mediated immune responses. 2. To preliminarily evaluate the efficacy of different dose levels of AVL-101 injection administered three times at 3-week intervals for the treatment of CIN2/3 caused by HPV16/18 infection. Exploratory Objectives: 1. To explore the PK characteristics, i.e., DNA exposure level, of subjects after the first administration of AVL-101 injection. 2. To explore the levels of relevant cytokines in peripheral blood before and after administration of AVL-101 injection.